Lynn Shepherd is one of the country’s leading health care communications practitioners, having represented the full spectrum of health care stakeholders through senior agency and in-house roles over the past 25 years.
Most recently, Lynn led communications at health tech startups, CareCloud and Accolade. Prior to Accolade, Lynn was global director of communications at the big data company, IQVIA, where she led communications to support the company’s digital health, real-world evidence, government and payer/provider solutions. She also served as corporate spokesperson and led various thought-leadership programs on real-world evidence and prescription access for pharmaceutical company, AstraZeneca. Lynn held a similar role at health insurer, CIGNA, where she served as a spokesperson and led initiatives to support the company’s relationships with health systems and medical group practices in the Mid-Atlantic region while developing national women’s health platform programs to promote consumer, customer and provider engagement. Her extensive communications agency experience includes leading the health care practice at Fleishman-Hillard’s Washington, DC office, where she led national campaigns and announcements for clients including the Center for Studying Health System Change, the American Academy of Medical Acupuncture, the American Legacy Foundation and Celera Genomics.
Lynn has received numerous awards for her work, including three PRSA Silver Anvil Awards, and was honored with the Health Care Businesswomen’s Association Rising Star award in 2005. Lynn’s personal mission is to accelerate the adoption of innovative health care technologies, therapies and approaches through communications. In her spare time, she conducts communications workshops and coaching for startups at the Cambridge Innovation Center in Philadelphia.
Lynn earned her master’s degree in communications management from Syracuse University’s SI Newhouse School of Communications and her bachelor’s degree in English literature from Penn State University.